Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye

• US 20060251685A1
• Filed: 05/03/2006
• Published: 11/09/2006
• Est. Priority Date: 03/18/2003
• Status: Abandoned Application

• Current Assignee: Advanced Medical Optics Incorporated (Johnson & Johnson)
• Original Assignee: Advanced Medical Optics Incorporated (Johnson & Johnson)
• Inventors: Crawford, Lauren, Yu, Zhi-Jian
• Application Number:
  US11/418,486
• Publication Number:
  US 20060251685A1
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 36/535 Perilla (beefsteak plant)
• CPC Class Codes: A61K 36/55 Linaceae (Flax family), e.g. Linum
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61P 27/04 Artificial tears; Irrigation solutions

Abstract

An ophthalmic composition includes oil globules dispersed in an aqueous phase. The globules include a surfactant component, a polar oil component that includes an Omega-3 fatty acid and a viscosity modifying agent. The surfactant to oil ratio produces an average size of globules of about 0.1 microns or less. The viscosity is at least as viscous as 0.25% 800K sodium hyaluronate. The composition can be used for treatment of dry eye. The compositions are stable and can have anti-microbial activity sufficient for use as contact lens disinfecting solutions.

Claims

1. An ophthalmic composition comprising:

oil globules dispersed in an aqueous phase, said globules comprising;

(a) a surfactant component;

(b) a polar oil component comprising an Omega-3 fatty acid, wherein the surfactant to oil ratio is adjusted such that said oil globules have an average size of about 0.1 micron or less; and

(c) a viscosity modifying agent in a concentration that produces a viscosity at least as viscous as 0.25% 800K (w/w) Sodium Hyaluronate.

2. The composition of claim 1, wherein the surfactant component consists essentially of one or two surfactants.

3. The composition of claim 1, wherein the surfactant to oil ratio is adjusted to obtain oil globules having an average size of about 0.08 micron or less.

4. The composition of claim 1, wherein the surfactant to oil ratio is adjusted to obtain oil globules having an average size of about 0.05 micron or less.

5. The composition of claim 1, wherein the Omega-3 fatty acid component is selected from a natural oil that is a source of Omega-3 fatty acids.

6. The composition of claim 1, wherein the Omega-3 fatty acid component is selected from a synthetic oil that is a source of Omega-3 fatty acids.

7. The composition of claim 5, wherein the Omega-3 fatty acid component is from flaxseed oil.

8. The composition of claim 5, wherein the Omega-3 fatty acid component is from Perilla seed oil.

9. The composition of claim 1, wherein the composition is self-emulsifying.

10. The self-emulsifying composition of claim 9, wherein the surfactant component has a hydrophobic portion which comprises a first part oriented proximal to the aqueous phase that is larger than a second part of the hydrophobic portion of the surfactant component oriented towards the interior of the oil globule.

11. The self-emulsifying composition of claim 9, wherein the surfactant component consists essentially of one surfactant with the first part of the hydrophobic portion of the surfactant that contains more atoms than the second part of the hydrophobic portion of the surfactant.

12. The self-emulsifying composition of claim 9, wherein the surfactant component consists essentially of two surfactants, a first of said surfactants comprising a first hydrophobic portion and a second of said surfactants comprising a second hydrophobic portion, said first hydrophobic portion having a longer chain length than the second hydrophobic portion.

13. A self-emulsifying composition according to claim 9, further comprising an additional surfactant that does not interfere with self-emulsification.

14. The self-emulsifying composition of claim 9, wherein the surfactant component is selected from the group consisting of (a) a compound having at least one ether formed from at least about 1 to 100 ethylene oxide units and at least one fatty alcohol chain having from at least about 12 to 22 carbon atoms;

(b) a compound having at least one ester formed from at least about 1 to 100 ethylene oxide units and at least one fatty acid chain having from at least about 12 to 22 carbon atoms;

(c) a compound having at least one ether, ester or amide formed from at least about 1 to 100 ethylene oxide units and at least one vitamin or vitamin derivative; and

(d) combinations thereof consisting of no more than two surfactants.

15. The self-emulsifying composition of claim 9, wherein the surfactant component is selected from the group consisting of Lumulse GRH-40 and TPGS.

16. The self-emulsifying composition of claim 9, wherein the surfactant component is Lumulse GRH-40.

17. The composition of claim 1, wherein the pH of the composition is in the range of about 6.5 to about 8.5.

18. The composition of claim 17, wherein the pH of the composition is in the range of about 7.3 to about 7.7.

19. The composition of claim 1, wherein the osmolality of the composition is from about 250 to about 330 mOsm/kg.

20. The composition of claim 19, wherein osmolality of the composition is from about 270 to about 310 mOsm/kg.

21. The composition of claim 1, formulated as a multipurpose solution for contact lenses.

22. A method of preparing the composition of claim 1 comprising:

preparing an oil phase comprising an Omega-3 fatty acid and a surfactant component, wherein the Omega-3 fatty acid and the surfactant component in the oil phase are in the liquid state;

preparing an aqueous phase at a temperature that permits self-emulsification;

wherein the aqueous phase comprises the viscosity modifying agent; and

mixing the oil phase and the aqueous phase to form an emulsion, without mechanical homogenization.

23. A method of preparing a composition according to claim 22, further comprising forming a milky paste or a clear viscous gel between the oil phase and a part of the aqueous phase and mixing the paste or gel with the rest of the aqueous phase to form an emulsion.

24. The method of preparing an ophthalmic composition according to claim 22, wherein the viscosity modifying agent is selected from the group consisting of hyaluronic acid and salts thereof, polyvinylpyrrolidone (PVP), cellulose polymers, including hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), ethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose and carboxymethyl cellulose (CMC), dextran 70, gelatin, glycerine, polyethylene glycols, polysorbate 80, propylene glycol and povidone.

25. The method of preparing an ophthalmic composition according to claim 22, wherein the viscosity modifying agent is selected from the group consisting of carbomers (e.g. carbopol RTM), polyvinyl alcohol, alginates, carrageenans, and guar, karaya, agarose, locust bean, tragacanth and xanthan gums.

26. The method of claim 24, wherein the cellulose polymer is carboxymethylcellulose (CMC) or hydroxypropyl methylcellulose.

27. The method of claim 24, wherein the polyethylene glycol is PEG 300 or PEG 400.

28. The method of preparing an ophthalmic composition according to claim 22, wherein the surfactant component consists essentially of one or two surfactants.

29. A method of treating dry eye in an individual comprising administering a composition according to claim 1 directly to an eye of the individual.

30. A method of treating dry eye in an individual comprising administering a composition according to claim 5 directly to an eye of the individual.

31. A method of treating dry eye in an individual comprising administering a composition according to claim 15 directly to an eye of the individual.

32. An ophthalmic composition comprising:

oil globules dispersed in an aqueous phase, said globules comprising;

(a) a surfactant component;

(b) a polar oil component comprising an Omega-3 fatty acid; and

(c) a polymeric quaternary amine preservative in an amount sufficient to produce a composition that meets U.S. preservative efficacy testing standards.

33. The composition of claim 32, wherein the polymeric quaternary amine preservative has an HLB value significantly higher than the HLB value of the polar oil component.

34. The composition of claim 32, wherein sufficient amounts of polymeric quaternary amine preservative are added to meet European preservative efficacy standards.

35. The composition of claim 32, wherein the polymeric quaternary amine preservative is selected from the group consisting of poly[dimethylimino-w-butene-1,4-diyl]chloride, alpha-[4-tris(2-hydroxyethyl)ammonium]dichloride (Polyquaternium 1®

), poly(oxyethyl(dimethyliminio)ethylene dmethyliminio)ethylene dichloride (WSCP®

), polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB).

36. The composition of claim 35, wherein the wherein the polymeric quaternary amine preservative is ispolyhexamethylene biguanide (PHMB).

37. The composition of claim 32, wherein the concentrations of the polymeric quaternary amine preservative range from about 0.00001% to about 2% (w/v).

38. The composition of claim 32, wherein the concentrations of the polymeric quaternary amine preservative range from about 0.00005% to about 1% (w/v).

39. The composition of claim 32, wherein the concentrations of the polymeric quaternary amine preservative is about 0.0001% (w/v).

40. The composition of claim 32, wherein the polymeric quaternary amine preservative is present at an ophthalmically acceptable or safe concentration such that the user can remove the disinfected lens from the composition and thereafter directly place the lens in the eye for safe and comfortable wear.

41. A method of treating dry eye in an individual comprising administering a composition according to claim 32 directly to an eye of the individual.

42. A method of treating dry eye in an individual comprising administering a composition according to claim 35 directly to an eye of the individual.

43. A method of treating dry eye in an individual comprising administering a composition according to claim 36 directly to an eye of the individual.